IP Library Granted Patent US 10,775,322
Granted Patent B2
US 10,775,322 · App. 15/183,149 · Granted Sep 15, 2020

Inert crystal delivery medium for serial femtosecond crystallography

Inventors: Chelsie Conrad (Phoenix, AZ); Petra Fromme (Mesa, AZ); Daniel James (Mesa, AZ); Christopher Kupitz (Scottsdale, AZ)
Assignee: Arizona Board of Regents on Behalf of Arizona State University
G01N23/2005C30B7/14C30B29/58G01N33/483
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,775,322
App. No.
15/183,149
Granted
Sep 15, 2020
Kind
B2
Abstract

A system and method for preparing a crystal delivery medium comprising agarose for serial femtosecond crystallography and uses thereof.

Claims (18)

1. A method for preparation of an inert crystal delivery medium, the method comprising the steps of: preparing an agarose solution comprising agarose, a cryoprotectant, and a first crystallization buffer; preparing a crystal solution comprising a plurality of ordered and symmetrically packed membrane-bound protein crystals and a second crystallization buffer, wherein membrane-bound protein of the membrane-bound protein crystals is insoluble in water; and mixing the crystal solution and the agarose solution such that the plurality of membrane-bound protein crystals are suspended within the agarose solution to form an inert crystal delivery medium comprising the plurality of membrane-bound protein crystals, 5.5%-10% (w/v) agarose, the cryoprotectant, the first crystallization buffer, and the second crystallization buffer.

2. The method of claim 1 , wherein the crystal solution is contained within a first syringe, the agarose solution is contained within a second syringe, and the first and second syringes are coupled to mix the crystal solution and agarose solution and, thereby, form the inert crystal delivery medium.

3. The method of claim 1 , wherein the cryoprotectant is provided at a concentration sufficient to prevent formation of ice.

4. The method of claim 1 wherein the first crystallization buffer of the agarose solution and the second crystallization buffer of the crystal solution are the same crystallization buffer.

5. The method of claim 1 , wherein the plurality of the membrane-bound protein crystals comprises crystals of between 100 nm to 40 μm in size.

6. The method of claim 5 , wherein the crystals are between 1 to 10 μm in size.

7. A crystal delivery medium, the medium comprising:

ordered and symmetrically packed membrane-bound protein crystals, wherein membrane-bound protein of the membrane-bound protein crystals is insoluble in water;

5.5%-10% (w/v) agarose;

a cryoprotectant; and

a crystallization buffer.

8. The medium of claim 7 , wherein the cryoprotectant is a polyethylene glycol.

9. The medium of claim 7 , wherein the cryoprotectant is a sugar.

10. The medium of claim 7 , wherein the cryoprotectant is provided at a concentration sufficient to prevent formation of ice.

11. The medium of claim 7 , wherein the cryoprotectant is selected from the group consisting of polyethylene glycols, glycerol, ethylene glycol, non-volatile organics, osmolytes, polyols, sugars, oils, and mixtures thereof.

12. The medium of claim 11 , wherein the cryoprotectant is selected from the group consisting of polyethylene glycols, glycerol, ethylene glycol, sugars, and mixtures thereof.

13. A system for preparation of a crystal delivery medium for serial femtosecond crystallography, the system comprising: ordered and symmetrically packed membrane-bound protein crystals, wherein the membrane-bound protein of the membrane-bound protein crystals is insoluble in water; an agarose solution comprising 5.5%-10% (w/v) agarose, a cryoprotectant, and a crystallization buffer; and a first syringe, a second syringe, and a syringe coupler for mixing the membrane protein crystals into the agarose solution.

14. The system of claim 13 , wherein the cryoprotectant is provided at a concentration sufficient to prevent formation of ice.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2016
From: CONRAD, CHELSIE; FROMME, PETRA; JAMES, DANIEL; KUPITZ, CHRISTOPHER
To: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
Reel/Frame 039449/0912 →
CONFIRMATORY LICENSE Recorded Jul 13, 2016
From: ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039323/0188 →
Continuity (2)
Provisional Application 62180326 · Jun 16, 2015
Related Publication 20160370306A1 · Dec 22, 2016